0000928054-25-000098
SEC filingFlotek's Q3 2025 revenue rose 13% YoY, driven by PWRtek rentals and contract shortfall fees, with net income surging to $20.4M.
Flotek reported consolidated revenue of $56.0 million for Q3 2025, a 13% increase from $49.7 million in Q3 2024. The growth was primarily driven by $6.1 million in PWRtek rental revenue within the Data Analytics segment and a $1.9 million increase in accrued Contract Shortfall Fees from the ProFrac supply agreement. Gross profit surged 95% to $17.8 million, and gross margin expanded from 18.3% to 31.7%, reflecting lower cost of sales as a percentage of revenue (68.3% vs. 81.7%) and a favorable revenue mix shift toward higher-margin PWRtek rentals. Income from operations rose to $9.1 million compared to $2.7 million in the prior year, an increase of $6.4 million, driven by the gross profit improvement partially offset by a $1.7 million rise in SG&A expenses and $0.2 million in asset acquisition costs. Net income reached $20.4 million versus $2.5 million, boosted by a $12.6 million income tax benefit from the partial release of the valuation allowance. Operating margin improved from 5.5% to 16.2%.
Chemistry Technologies (CT): External revenue grew 43% YoY to $20.2 million in Q3 2025, driven by increased activity. Related-party revenue fell 18% to $27.0 million, as decreased ProFrac purchases were partially offset by higher Contract Shortfall Fees. Segment operating income rose to $8.5 million from $5.6 million, supported by $3.6 million in additional gross profit. For the nine-month period, CT operating income increased $7.7 million to $25.5 million.
Data Analytics (DA): External revenue increased 10.3% to $2.7 million, while related-party revenue surged $5.9 million to $6.1 million, primarily from PWRtek rental income. Segment operating income swung from $0.1 million in Q3 2024 to $4.4 million in Q3 2025, with the operating margin reaching 49.4%. For the nine-month period, DA revenue more than doubled to $17.4 million, and operating income rose $3.0 million to $2.3 million despite $4.4 million in asset acquisition expenses.
Corporate and Other: Loss from operations widened by $0.8 million to $3.8 million in Q3 2025, attributed to increased professional fees.
Management expects stable demand for CT chemistry through 2025, supported by strong first-quarter results and customer commitments, with longer-term growth anticipated from international unconventional activity in the Middle East and Argentina. The DA segment is positioned for significant growth, with the Lease Agreement with ProFrac expected to generate approximately $27.0 million in full-year 2026 revenue alone, compared to $17.4 million from all DA sources in the first nine months of 2025. The Company's outlook is tempered by the cyclical nature of oil and gas, but it believes fundamentals for energy services remain stable. Capital resources are expected to be sufficient over the next twelve months, supported by cash on hand, operating cash flow from the ProFrac and Lease agreements, and $8.5 million in available borrowings under the ABL as of November 5, 2025.
As of September 30, 2025, Flotek held $4.6M in cash and equivalents (plus $0.1M restricted cash). Total debt stood at $46.6M, comprising $39.6M net related party note (PWRtek Note, 10% interest, due 2030), $6.7M under the ABL facility (Prime+2%, maturing August 2026), and $0.4M in finance lease liabilities. Shareholders' equity was $110.5M, with an accumulated deficit of $288.8M. Inventory totaled $13.2M (net of $4.5M reserve). The ABL had $9.6M of available borrowings; the company was in compliance with covenants.
Flotek has future lease payment obligations of $9.3M ($8.9M operating, $0.5M finance) as of September 30, 2025. The operating lease maturities extend to 2030, with $2.3M due within one year. Additionally, the company has a contract asset of $64.8M (net) representing future revenue from the ProFrac Agreement, amortized over its remaining term through May 2032. The PWRtek Note requires a $40M principal payment at maturity in 2030, with quarterly interest at 10%.
No share buybacks or dividends were executed during the nine-month period. Capital expenditures were $1.7M (1.0% of revenue), primarily for property and equipment. Debt activity included the issuance of the $40M PWRtek Note (net $39.6M) and net draws of $1.9M on the ABL. The company also fully repaid the $0.4M PPP loan. The PWRtek Note sale in November 2025 enabled prepayment flexibility but retained the principal obligation.
Chemistry Technologies generated $152.3M revenue (89.7% of total), with operating income of $25.5M (16.7% margin). Data Analytics revenue rose to $17.4M (10.3% of total), driven by $9.3M in rental income from the PWRtek lease acquisition. The DA segment posted operating income of $2.3M (13.4% margin). Geographically, U.S. revenue accounted for $159.7M (94.1% of total), with UAE at $8.9M and other countries at $1.1M. Long-lived assets outside the U.S. were immaterial.
Net income for the nine months ended September 30, 2025 was $27.50M, a significant increase from $6.07M in the prior year. However, net cash provided by operating activities fell sharply to $0.96M from $5.93M, indicating a large divergence between accrual earnings and cash generation. The primary driver was a massive swing in working capital: accounts receivable (including related party) consumed $19.95M in cash (vs. a $11.15M use in 2024), and accounts payable decreased by $3.00M (vs. a $5.69M increase). A large deferred income tax benefit of $12.77M also reduced cash flow from operations. Capital expenditures increased to $1.70M from $0.49M, raising capex intensity. Free cash flow (CFO minus capex) was negative $0.74M, compared to positive $5.43M in the prior period. There were no share repurchases or dividends paid. Financing activities provided $1.08M, primarily from net asset-based loan proceeds, offset by debt payments and issuance costs. The company ended the period with $4.71M in cash and restricted cash, up slightly from $4.51M at the start of the period.